Key facts
- Notable investors include BVCF.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for QiSeLian Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for QiSeLian Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About QiSeLian Biotechnology
Developer of personalized cell therapy and anti-aging biomedicine aims to accelerate the clinical and commercial adoption of personalized regenerative therapies and anti-aging treatments. The company's offerings feature standardized, scalable iPSC cell-resource platforms, proprietary preclinical iPSC applications in anti-aging and disease-specific regeneration, and integrated health-management services including genetic testing and cell banking, enabling clinical research acceleration, enhanced treatment personalization, and improved long-term health outcomes.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2025
- Website
- 7selian.com/
- Ownership
- Privately Held (backing)
QiSeLian Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in QiSeLian Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on QiSeLian Biotechnology in its N-PORT filings yet. We sweep new filings monthly.